Announcement of receiving the "Regenerative medicine Innovation Award" at the 23rd Annual Meeting of the Japanese Society Regenerative medicine
February 8, 2024
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Masafumi Sugimoto) is pleased to announce that it has been selected as one of the Established Company recipients (2 companies) in the "Regenerative Regenerative medicine Innovation Award" held at the 23rd Annual Meeting of the Japanese Regenerative medicine.
This award recognizes ambitious companies that are developing unique Regenerative medicine technologies originating in Japan.
In recognition of this award, I am scheduled to participate in the award ceremony and give a commemorative lecture at the General Assembly to be held in Niigata from March 21st to 23rd, 2024.
About Rohto Pharmaceutical's Regenerative medicine
Our company has adopted "Connect for Well-being" as ROHTO Group Comprehensive Management Vision 2030, and we are developing various businesses with the aim of becoming a company that provides all kinds of solutions related to health and beauty.
With the aim of providing Regenerative medicine as a new treatment option to patients who are suffering from a lack of appropriate treatment, we have embodied this desire in Regenerative medicine business statement, "Making Regenerative medicine more accessible and easier to use." We are working towards the social implementation of regenerative medicine through initiatives such as translational research on mesenchymal stem cells, collaborative research with academia and research institutions aimed at promoting cutting-edge technology development, participation in cross-innovation hubs, establishing a system for domestic manufacturing of all processes from human tissue acquisition to final products, contract processing services for clinics that provide private medical care, development and manufacturing outsourcing (CDMO) services, and development and sales of Regenerative medicine.
In addition to Regenerative medicine research utilizing the "cell handling technology" cultivated through the research and development of skincare products and the "sterile formulation technology" cultivated through the manufacture of eye drops, we aim to leverage our technological capabilities in cell processing and formulation as a new strength, collaborating with the latest technologies and medical facilities both domestically and internationally to contribute to the spread of Regenerative medicine and the development of related industries.
About the "Regenerative medicine Innovation Award"
the purpose
This project recognizes companies that are working on developing unique Regenerative medicine technologies originating in Japan, and celebrates their achievements and contributions.
Award recipients
- Companies that conduct research and development of superior Regenerative medicine technologies, and whose results are progressing toward practical application and clinical use.
- A company that provides social and economic value in the field of Regenerative medicine and contributes to the development of the health industry.
- Companies that conduct excellent activities from an environmental and ethical standpoint.
https://www.congre.co.jp/jsrm2024/contents/award.html